Lumisight Injection, Powder, Lyophilized, For Solution
NDC Package 82292-040-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Lumisight (pegulicianine) injection is lUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Lumicell, Inc., this product is identified by NDC 82292-040 and is authorized under FDA application NDA214511.

Identification & Billing

NDC Package Code
82292-040-10
Package Description
10 VIAL in 1 CARTON / 3.9 mL in 1 VIAL (82292-040-01)
Product Code
82292-040
11-Digit Billing Format
82292004010
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA

Clinical Specifications

Proprietary Name
Lumisight
Non-Proprietary Name
Pegulicianine
Substance Name
Pegulicianine
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
PEGULICIANINE 10 mg/mL
Usage Information
LUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery.

Regulatory & Marketing

Labeler Name
Lumicell, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA214511
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-17-2024
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

A9615
Source: OPPS
Inj, pegulicianine, 1 mg
HCPCS Dosage 1 MG
Units / Pkg 390

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 82292-040-10 identifies a specific commercial package of 10 vial in 1 carton / 3.9 ml in 1 vial (82292-040-01) of Lumisight, a human prescription drug labeled by Lumicell, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains pegulicianine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lumicell, Inc. on April 17, 2024. The current certification is valid through December 31, 2027.

How is this Lumicell, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 82292004010. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
82292-040-10
11-Digit CMS (5-4-2)
82292-0040-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.